Fig. 1

Lung CSCs were successfully enriched from A549 and SPC-A1 cells. A, B Flow cytometric analysis results demonstrating the percentage of tumorigenic CD44+ A549 and SPC-A1 cells. C, D CD44+ A549 and SPC-A1 CSCs were analyzed using anti-Bach1, anti-CD44, anti-Sox2, anti-Nanog and anti-Oct4 antibodies using western blotting. E Tumor volume was shown in the two different groups. Mice were injected with CD44+ A549 and CD44− cells. F Ki-67-positive cell ratios. G Bach1 protein expression was evaluated using IHC western blot analysis. *P < 0.05, ***P < 0.001